MYD88 and diffuse large B-cell lymphoma: Early WES studies of DLBCL, showed recurrent mutations in MYD88, CARD11, EZH2, and CREBBP, which were known to be altered in DLBCL and somatic mutations in novel genes like MEF2B, MLL2, BTG1, GNA13, ACTB, P2RY8, PCLO, and TNFRSF14 (146).